Immunotherapy combinations (e.g., Nivolumab + Ipilimumab)

Type: drug

Status: FDA Approved

Developer: Bristol Myers Squibb

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026